The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early-onset colorectal cancer: Real-world genomic data from the community-based Sarah Cannon Cancer Centers Network.
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Consulting or Advisory Role - Astellas Pharma (I); Bristol-Myers Squibb (I); Celgene (I); SERVIER (I)
Patents, Royalties, Other Intellectual Property - Patent No: 1716712.3 pending (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); SERVIER (I)
 
Carissa Jones
Employment - HCA/Sarah Cannon
 
Amanda Misch
No Relationships to Disclose
 
Daniel Schlauch
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - HCA Healthcare
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curio Science (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evidera (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intellisphere (Inst); Ipsen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Molecular Templates (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Hendrik-Tobias Arkenau
Employment - Hospital Corporation of America
Honoraria - Bayer; BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER
Consulting or Advisory Role - Engitix; iOnctura
Research Funding - Sarah Cannon Research Institute
 
Andrew Jacob McKenzie
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare